- Olanzapine as pamoate monohydrate is a long-acting injectable or depot form of olanzapine and provides another option for maintenance treatment of schizophrenia.
- It is administered by deep intramuscular gluteal injection only, every 2 weeks or every 4 weeks.
- There is a risk of post-injection syndrome with every dose of olanzapine depot injection.
- Monitor for signs and symptoms of post-injection syndrome (sedation and/or delirium) for at least 3 hours after each dose.
- As with oral olanzapine, weight gain and metabolic effects (raised serum cholesterol, triglyceride and glucose levels) are common.
- Establish tolerability and response to oral olanzapine before switching to the depot formulation.
- Consider depot antipsychotic therapy in people unable or unwilling to adhere with oral medication, and in those who prefer depot injections to oral therapy.
Reason for PBS listing
The Pharmaceutical Benefits Advisory Committee recommended olanzapine depot injection for listing consistent with the listings of other long-acting antipsychotic injections for the treatment of schizophrenia.1
Place in therapy
Olanzapine as pamoate monohydrate is a long-acting injectable or depot form of olanzapine. It is approved for maintenance treatment of schizophrenia in adults sufficiently stabilised during acute treatment with oral olanzapine.2 It is given by deep intramuscular (IM) gluteal injection every 2 or every 4 weeks.
The PBS listing of olanzapine depot injection provides an additional long-acting atypical antipsychotic option to risperidone IM long-acting injection, the only other depot atypical antipsychotic approved (and PBS listed) for maintenance treatment in schizophrenia.
Other antipsychotic depot options include the typical antipsychotics depot flupenthixol, fluphenazine, haloperidol and zuclopenthixol. Without a head-to-head, controlled comparison trial it is unclear how much depot olanzapine's effectiveness, safety, tolerability and patient acceptability differs from that of depot risperidone and other depot antipsychotics.
Establish tolerability and response with oral olanzapine (tablets or wafers) in olanzapine naïve patients before starting treatment with olanzapine depot injection.2 There is no published information about switching patients stabilised on other antipsychotics directly to olanzapine depot injection and this is not consistent with the TGA-approved indication.
Do not confuse with rapid-acting IM formulation for use in acute care
There are two IM formulations of olanzapine and these should not be confused:
- olanzapine (Zyprexa IM) 10 mg powder for IM injection (rapid-acting) reconstituted with sterile water for injection
- olanzapine (as pamoate monohydrate) depot injection (Zyprexa Relprevv) 210 mg, 300 mg or 405 mg* powder and sterile diluent for IM injection.
*Olanzapine depot injection 405 mg is currently not available in Australia.
When to consider depot antipsychotic injections
Medication non-adherence is common and associated with poorer outcomes in people with schizophrenia.3,4Depot antipsychotic therapy is an option when medication adherence is inadequate despite appropriate psychosocial interventions aimed at improving adherence, and for people who prefer long-acting antipsychotic injections to oral therapy.5–8
Choose between antipsychotics based on the relative risks and benefits of individual drugs, and patient preference.5,9
Review the need for depot antipsychotic therapy regularly.6
Psychological and psychosocial interventions may improve adherence
Consider tailored psychological and psychosocial interventions as an adjunct to drug therapy to improve outcomes for people with schizophrenia.5,6,8,9 There is some evidence that family-based interventions, psychoeducational interventions and behavioural therapies may improve medication adherence compared with usual care10,11 but no consistent evidence for the effectiveness of compliance therapy.12
Efficacy in acutely ill and stabilised patients with schizophrenia
The efficacy of olanzapine depot injection was compared with placebo in acutely ill patients, and with oral olanzapine in patients previously stabilised on oral olanzapine.13,14 There are no controlled data directly comparing olanzapine depot injection with any other depot antipsychotics in the treatment of schizophrenia.
In a short-term trial (8 weeks' duration) patients randomised to olanzapine long-acting injection achieved greater mean decreases from baseline in the positive and negative syndrome scale (PANSS†) total score compared with those randomised to placebo.13
In an unpublished 24-week maintenance trial, olanzapine depot injection (300 mg / 2 weeks pooled with 150 mg / 2 weeks) was no less effective than oral olanzapine (10–20 mg daily) in terms of exacerbation of symptoms in patients previously stablised on fixed doses of oral olanzapine (exacerbation rates 10% versus 7% with oral olanzapine, 95% confidence interval –0.02 to 0.08).14 All 3 doses of olanzapine depot injection used in the trial (405 mg / 4 weeks, 300 mg / 2 weeks and 150 mg / 2 weeks) were more effective than control (45 mg / 4 weeks) in maintaining response.14
By the end of the study, patients randomised to oral olanzapine had achieved numerically lower symptom scores (mean decrease from baseline PANSS total score) compared with those randomised to olanzapine depot injection. These results might be partially explained by inadequate dosing with depot olanzapine for patients previously stabilised on fixed doses of oral olanzapine. While some patients were randomised to continue on the dose of oral olanzapine at which they demonstrated a response, others may have been randomised to a dose of olanzapine depot injection that was not equivalent to their preceding oral olanzapine dose.15 Recommended starting doses for olanzapine depot injection are higher than the daily oral doses to minimise the risk of exacerbation.
†The PANSS is a 30-item, 7-point rating instrument used to measure the prevalence and severity of positive and negative symptoms and general psychopathology in schizophrenia (range 30 = symptom not present to > 200 = symptom extremely severe).15,16
Trial populations may not resemble those for whom depot antipsychotic medication is recommended and likely to be used
Current guidelines recommend the use of depot antipsychotics for people with schizophrenia for whom adherence is a problem.5,6,8 Medication adherence was not assessed formally either before or during key studies, but it is conceivable that patients may have been more co-operative than the target population for this drug, as evidenced by their willingness to participate in trials. Discontinuation rates were nevertheless high in a placebo-controlled trial (around 33% for olanzapine depot injection versus 43% for placebo), where patients received a high level of supervision (83% of participants remained inpatients throughout the study)13, and may be even higher in real-life settings. Interim results from a long-term (4-year) open-label trial showed that 28% of patients had discontinued from the trial at 1 year and 34% had discontinued at 18 months.14
Key trials excluded people with acute, serious or unstable medical conditions or concomitant substance use disorders, and significant suicidal or homicidal risk.13,17 In reality the prevalence of physical and psychiatric comorbidity and substance abuse in people with schizophrenia is well documented.18,19
Limited trial data suggest that the adverse effect profile of olanzapine depot injection may be similar to that of oral olanzapine, with the exception of post-injection syndrome (see below) and injection-site pain. Weight gain and lipid parameters were similar between patients treated with oral olanzapine and those treated with olanzapine depot injection.20 Higher-dose regimens (300 mg / 2 weeks) were associated with statistically higher mean changes in weight, serum prolactin levels and fasting triglyceride levels post baseline compared with lower-dose regimens (405 mg / 4 weeks and 150 mg / 2 weeks).15,20
However, olanzapine depot injection is a new formulation with few published safety data from controlled trials; there is therefore some extra uncertainty about its safety profile.
Report suspected adverse reactions to the Therapeutic Goods Administration (TGA) online or by using the 'Blue Card' distributed 3 times a year with Australian Prescriber. For information about reporting adverse reactions, see the TGA website.
The risk of post-injection syndrome remains with every injection
Post-injection syndrome includes a range of signs and symptoms of sedation (ranging from mild sedation to deep sleep and coma) and/or delirium (including confusion/confused state, anxiety and agitation) consistent with olanzapine overdose.14 Other symptoms include dizziness, weakness, altered speech/dysarthria, hypertension and seizures.14,15,20 Post-injection syndrome was reported for 0.07% of injections and in about 1.4% of trial participants.15
Most events occurred after repeated injection (several months of treatment).14 In case reports, events typically started with mild symptoms that progressed in severity. In most cases (84%), initial signs and symptoms occurred within the first hour after injection, but onset after 3 hours has been reported.14,15
Accidental contact between olanzapine and blood (inadvertent intravascular injection, or haematoma development) is a possible causal factor.14 Higher doses and therefore larger final volume for injection, increased age and low body mass index (BMI) may confer a higher risk for post-injection syndrome; however, events have occurred in patients not meeting these criteria.14
Monitor for alertness every 30 minutes for at least 3 hours after every injection
Check that the patient is alert, orientated and free of any other signs of post-injection syndrome every 30 minutes for at least 3 hours after each injection.14 Olanzapine depot injection should only be administered by an appropriately trained health professional in a healthcare facility with access to emergency services for the treatment of post-injection syndrome.2
Patients should not be alone after the observation period because events have been reported more than 3 hours post-injection.2 Warn patients and carers about possible signs and symptoms of post-injection syndrome and the need for urgent medical attention if they occur.2
The metabolic adverse effects of oral olanzapine can also be expected with olanzapine depot injection. Weight gain is common and can be rapid.13,14 Guidelines recommend measuring weight and body mass index every 3 months during treatment with antipsychotic medication.6 Consider offering advice on diet and exercise to prevent weight gain or promote weight loss.8,9,21 Non-pharmacological interventions (individual and group therapy, cognitive behavioural therapy and nutritional counselling) have been shown to reduce antipsychotic-induced weight gain compared with usual care.21
Monitor fasting plasma glycated haemoglobin (HbA1c) and lipid levels at least every 6 months for people taking olanzapine.5 Regular screening for metabolic syndrome (3–6 monthly) is recommended for all patients receiving any antipsychotic medication.5,6,22
Olanzapine depot injection should not be given to olanzapine naïve patients. Establish tolerability and response with oral olanzapine before switching to the recommended starting dose of olanzapine depot injection (seeTable 1).
Reconstitute with diluent provided to form a suspension. Administer by deep IM gluteal injection only, every 2 weeks or every 4 weeks. Each olanzapine pack includes 3 needles, 1 of which is a 19-gauge 50 mm safety needle for obese patients.23
If depot injections are required, guidelines recommend using the lowest therapeutic dose at the longest approved dosing interval consistent with desired therapeutic benefit.6,9 Dosing with olanzapine depot injection differs from other depots in the following ways:
- patients can be switched abruptly from oral to olanzapine depot injection; supplementation with oral olanzapine is not required at the start of treatment with depot olanzapine
- start with a higher dose than the established oral dose (see Table 1) and titrate downwards after 2 months if possible.
Table 1Recommended dosing and titration scheme when switching between oral olanzapine and olanzapine depot injection2
Daily oral olanzapine dose
Recommended starting dose of olanzapine depot injection
Maintenance dose after
210 mg / 2 weeks or
150 mg / 2 weeks or
300 mg / 4 weeks†
300 mg / 2 weeks
210 mg / 2 weeks or 405 mg*/ 4 weeks
300 mg / 2 weeks
300 mg / 2 weeks
|* Olanzapine depot injection 405 mg is currently not available in Australia. † There are no data from randomised controlled trials on the efficacy of olanzapine depot injection 300 mg / 4 weeks. Pharmacokinetic data indicate that plasma concentrations at this dose are similar to plasma concentrations achieved at the equivalent oral dose.2|
In a placebo-controlled trial, no statistically significant difference in baseline to endpoint PANSS total scores were observed between 2- and 4-week dosing regimens of olanzapine depot injection (210 mg / 2 weeks and 405 mg / 4 weeks) suggesting equivalence, but the study was not powered for this effect.13
Monitor carefully for signs and symptoms of exacerbation in the first 2 months of therapy. In a 6-month maintenance trial, most relapses occurred in the first 2 months of treatment with olanzapine depot injection in patients previously stabilised on oral olanzapine.15 However, the doses used during this period may have been lower than the recommended starting doses in Table 1.
Converting to oral olanzapine
If a decision is made to switch from olanzapine depot injection to oral olanzapine, gradually reduce the dose of olanzapine depot injection by the oral equivalent of 5 mg daily or 10 mg daily each month. At the same time gradually increase the dose of oral olanzapine by 5 mg daily or 10 mg daily.24
Information for patients
Advise patients and carers of the following.2,25
- Olanzapine depot injection is given every 2 or every 4 weeks as an injection into the muscle in your buttock.
- Some patients may need to continue oral olanzapine for a limited time after they start treatment with olanzapine depot injection, and at times when their symptoms are worse than usual.
- As with tablets or wafers, common side effects of olanzapine depot injection include weight gain, sleepiness, and increases in the levels of sugar and circulating fats in the blood.
- You will usually be asked to stay at the clinic/GP office for 3 hours after every injection so that you can be checked for symptoms of post-injection syndrome (including drowsiness, dizziness, confusion, disorientation, slurred speech, weakness). If you need to leave before this time you should ensure that you are accompanied by a friend or family member who can continue to observe you for these symptoms.
- Post-injection syndrome occurs in about 1 in 100 patients; it can occur after any dose of olanzapine depot injection.
- Be alert for symptoms of post-injection syndrome later than 3 hours after your injection and contact your GP or clinic immediately if these occur.
- Arrange for someone to accompany you to your destination after your injection. Do not drive or operate heavy machinery for the rest of the day after your injection.
Discuss the Zyprexa Relprevv consumer medicine information (CMI) leaflet with the patient.
- Australian Government Department of Health and Ageing. PBAC meeting outcomes: positive recommendations. July 2009. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacrec-jul09-positive (accessed 20 October 2009).
- Eli Lilly Australia Pty Ltd. Product information. Zyprexa relprevv. 9 October 2009.
- Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892\u2013909. [PubMed]
- Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453\u201360. [PubMed]
- Psychotropic writing group. Therapeutic guidelines: Psychotropic. Version 6. Melbourne: Therapeutic guidelines Limited, 2008.
- Royal Australian and New Zealand College of Psychiatrists. Clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005;39:1\u201330. [PubMed]
- Rossi S, ed. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2009.
- Falkai P WT, Lieberman J, Glenthoj B, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006;7:5\u201340. [PubMed]
- National Institute for Health and Clinical Excellence. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). 2009. http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11786 (accessed 17 August 2009).
- Pekkala ET, Merinder LB. Psychoeducation for schizophrenia (Review). Cochrane Database Syst Rev 2002;(2):CD002831. [PubMed]
- Pharoah F, Mari J, Rathbone J, et al. Family intervention for schizophrenia (Review). Cochrane Database Syst Rev 2006;(4):CD000088. [PubMed]
- McIntosh AM, Conlon L, Lawrie SM, et al. Compliance therapy for schizophrenia. Cochrane Database Syst Rev 2006;(3):CD003442. [PubMed]
- Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69:790\u20139. [PubMed]
- Eli Lilly and Company. Olanzapine Pamoate (OP) Depot, Psychopharmacologic Drugs Advisory Committee Briefing Document. 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4338b1-03-Lilly.pdf (accessed 3 August 2009).
- European Medicines Agency. Assessment report for zypadhera. 2008. http://www.emea.europa.eu/humandocs/Humans/EPAR/zypadhera/zypadhera.htm (accessed 3 August 2008).
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261\u201376. [PubMed]
- Eli Lilly and Company. Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia. NCT00088491. ClinicalTrialsgov Last Updated: June 20, 2007 http://clinicaltrials.gov/ct2/show/NCT00088491?term=nct00088491&rank=1 (accessed 3 August 2009).
- Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003;178:Suppl:S67\u201370. [PubMed]
- Fowler IL, Carr VJ, Carter NT, et al. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull 1998;24:443\u201355. [PubMed]
- Zhang J. Clinical review NDA 22-173, Olanzapine Pamoate Depot. 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4338b1-01-FDA.pdf (accessed 3 August 2009).
- Alvarez-Jim\u00e9nez M, Hetrick SE, Gonz\u00e1lez-Blanch C, et al. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008;193:101\u20137. [PubMed]
- Waterreus AJ, Laugharne JD. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust 2009;190:185\u20139. [PubMed]
- Eli Lilly Australia Pty Ltd. Physician training slides for Zyprexa Relprevv. 2009.
- Eli Lilly Australia Pty Ltd. Personal communication. 1 October 2009.
- Eli Lilly Australia Pty Ltd. Consumer medicine information. October 2009.